APREA THERAPEUTICS INC
APRENASDAQTrading Snapshot
- Day Range
- $0.76 – $0.78
- 52-Week Range
- $0.55 – $1.69
- Volume
- $2.24B
- Avg Volume
- $1.73B
- Shares Outstanding
- 12.4M
- Next Earnings
- Nov 4, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $600,076
- P/E Ratio
- -0.6
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.23
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +29.1%
Why Investors Own APRE
- ✓High-growth profile — revenue up -7.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 32% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
APREA THERAPEUTICS INC
APRE
StockOtter · stockotter.spaceAbout APREA THERAPEUTICS INC
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
DOYLESTOWN, Pa., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of ta
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
DOYLESTOWN, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of ta
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances
Lipocine Appoints Michael J. Grissinger to Board of Directors
SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announc
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with APR-1051